Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis

García-Valle, A.; Llano, Jesús M. Andrés-de; Fariña-González, Aarón Josué; González-Benítez, R.D.; Queiró, Rubén

doi:10.3899/jrheum.201362

Cited by 10 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also included 52 men and 38 women with PsA of mean age 55.3 ± 14.3 years, with a median arthritis duration of 7 years (IQR: 3–14) and a median psoriasis duration of 16 years (IQR: 10–29). The main disease features of these populations have been published elsewhere [ 13 , 14 , 15 ].…”

Section: Resultsmentioning

confidence: 99%

“…This is a post hoc comparative analysis of three multicenter observational cross-sectional studies in which we verified the construct and discriminant validity of the Assessment of SpondyloArthritis international Society-Health Index (ASAS HI) in axSpA [ 13 ] and PsA [ 14 ], as well as the construct/discriminant validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in axSpA [ 15 ]. The inclusion/exclusion criteria, methodological details, main results, and ethical considerations applicable to these studies have been published elsewhere [ 13 , 14 , 15 ]. This study complies with the declaration of Helsinki.…”

Section: Methodsmentioning

confidence: 98%

See 1 more Smart Citation

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes

Alonso-Castro

García-Valle

Morante

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Background and aims: The effect of smoking on disease activity and quality of life (QoL) in spondyloarthritis (SpA) is far from clear. We aimed to evaluate the relationship between smoking and these outcomes in patients with axial SpA (axSpA) and psoriatic arthritis (PsA). Patients and methods: This cross-sectional observational multicenter study included 242 patients with axSpA and 90 with PsA. The association between conventional cardiovascular risk factors and disease activity as well as QoL, in both SpA phenotypes was evaluated. For this, univariate and multivariate regression analyses were performed, as well as confirmatory meta-analyses. Results: Regardless of age, sex, or disease duration, patients with axSpA showed significantly less association with obesity (OR 0.50 (0.26–0.96), p = 0.03) and hypertension (OR 0.33 (0.18–0.62), p = 0.0005). However, axSpA was significantly associated with smoking (OR 2.62 (1.36–5.04), p = 0.004). Patients with axSpA were more likely to be in a category of high disease activity compared with PsA (OR 2.86, p = 0.0006). Regardless of sex, age, disease duration, and education level, smoking was significantly associated with higher disease activity in axSpA (OR 1.88, p = 0.027). A fixed-effects model meta-analysis (OR 1.70, p = 0.038) confirmed the association between tobacco and disease activity. No relationship was found between smoking (or other cardiometabolic risk factors) and structural damage or worse QoL in either disease. Conclusions: Although the cardiometabolic risk profile is clearly different between both SpA phenotypes, the only clear link between these factors and increased disease activity was observed between smoking and axSpA. Our findings need further confirmation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 98%

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes

Alonso-Castro

García-Valle

Morante

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, an alternative reading is also possible. We know that in other diseases, conventional DMARDs are independently associated with lower odds of achieving treatment goals ( 18 ). If a similar situation is occurring in PsA, this should be assessed in larger-scale studies.…”

Section: Discussionmentioning

confidence: 99%

Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo identify patient- and disease-related characteristics that make it possible to predict higher disease severity in recent-onset PsA.MethodsWe performed a multicenter observational prospective study (2-year follow-up, regular annual visits). The study population comprised patients aged ≥ 18 years who fulfilled the CASPAR criteria and less than 2 years since the onset of symptoms. Severe disease was defined at each visit as fulfillment of at least 1 of the following criteria: need for systemic treatment, Health Assessment Questionnaire (HAQ) > 0.5, polyarthritis. The dataset contained data for the independent variables from the baseline visit and follow-up visit number 1. These were matched with the outcome measures from follow-up visits 1 and 2, respectively. We trained a logistic regression model and random forest–type and XGBoost machine learning algorithms to analyze the association between the outcome measure and the variables selected in the bivariate analysis.ResultsThe sample comprised 158 patients. At the first follow-up visit, 78.2% of the patients who attended the clinic had severe disease. This percentage decreased to 76.4% at the second visit. The variables predicting severe disease were patient global pain, treatment with synthetic DMARDs, clinical form at diagnosis, high CRP, arterial hypertension, and psoriasis affecting the gluteal cleft and/or perianal area. The mean values of the measures of validity of the machine learning algorithms were all ≥ 80%.ConclusionOur prediction model of severe disease advocates rigorous control of pain and inflammation, also addressing cardiometabolic comorbidities, in addition to actively searching for hidden psoriasis.

show abstract

“…Moreover, the regular use of NSAIDs has been associated with a 5-fold increase in the odds of being in a higher disease impact category according to the ASAS health index, once again independently of biological drug use (17). Finally, in a recent study, after controlling for several confounders (including biologics use), NSAIDs intake was independently related to the odds of not reaching therapeutic goals as expressed by the Bath Ankylosing Spondylitis Disease Activity (BASDAI) remission criteria (OR 0.18), ASDAS inactive disease (OR 0.08), and Routine Assessment of Patient Index Data 3 (RAPID3) remission (OR 0.26) (18). Anyway, these observational studies are potentially exposed to several biases that may lead to misinterpretation of their results.…”

Section: Nsaids and Treatment Goals: Moving Closer Or Further Away?mentioning

confidence: 93%

Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?

et al. 2021

Self Cite

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of treatment for spondyloarthritides (SpA), a group of entities with common clinical and pathophysiological aspects, but also with differential features. Although NSAIDs provide significant symptomatic relief, especially for joint pain and morning stiffness, their role in achieving and maintaining the treatment goals advocated by the treat to target strategy in SpA is not entirely clear. These agents can induce changes in the composition of the intestinal microbiota, also favoring an alteration of the barrier function in the gut epithelium. All of this, favored by a pre-disposing genetic background, could activate a specific type of aberrant immune response in the gut lamina propria, also known as type-3 immunity. This article offers a perspective on how NSAIDs, despite their undeniable value in the short-term SpA treatment, could hinder the achievement of medium and long-term treatment goals by compromising the barrier function of the gut mucosa and potentially altering the composition of the gut microbiota.

show abstract

Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis

Cited by 10 publications

References 19 publications

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes

Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?

Contact Info

Product

Resources

About